Risk for Major Bleeding in Patients Receiving Ticagrelor Compared With Aspirin After Transient Ischemic Attack or Acute Ischemic Stroke in the SOCRATES Study (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes)

Easton J. D., Aunes M., Albers G. W., Amarenco P., Bokelund-Singh S., Denison H., ...More

CIRCULATION, vol.136, no.10, pp.907-934, 2017 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 136 Issue: 10
  • Publication Date: 2017
  • Doi Number: 10.1161/circulationaha.117.028566
  • Journal Name: CIRCULATION
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.907-934
  • Keywords: aspirin, hemorrhage, ischemic attack, transient, platelet aggregation inhibitors, stroke, P2Y(12) RECEPTOR ANTAGONIST, DOUBLE-BLIND, CLOPIDOGREL, INHIBITION, PREVENTION, RATIONALE, AZD6140, PLACEBO, DESIGN, MATCH
  • Eskisehir Osmangazi University Affiliated: No

Abstract

BACKGROUND: Patients with minor acute ischemic stroke or transient ischemic attack are at high risk for subsequent stroke, and more potent antiplatelet therapy in the acute setting is needed. However, the potential benefit of more intense antiplatelet therapy must be assessed in relation to the risk for major bleeding. The SOCRATES trial (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes) was the first trial with ticagrelor in patients with acute ischemic stroke or transient ischemic attack in which the efficacy and safety of ticagrelor were compared with those of aspirin. The main safety objective was assessment of PLATO (Platelet Inhibition and Patient Outcomes)-defined major bleeds on treatment, with special focus on intracranial hemorrhage (ICrH).